ADHD Screening in Post-Acute Care with GIA®
Attention Deficit Hyperactivity Disorder (ADHD) can significantly impact rehabilitation progress in post-acute care. [GIA®](/gia), integrated with [digitalhumanOS™](/platform), provides a valuable tool for identifying ADHD symptoms.
Key Facts
- ADHD can impact rehabilitation outcomes
- Adult ADHD often overlooked
- GIA® supports efficient ADHD screening
Attention Deficit Hyperactivity Disorder (ADHD) can significantly impact rehabilitation progress in post-acute care. GIA®, integrated with digitalhumanOS™, provides a valuable tool for identifying ADHD symptoms. By addressing attention deficits, therapists can tailor interventions to improve patient engagement and maximize rehabilitation outcomes.
PAC & ADHD
Unrecognized ADHD can hinder patient participation and progress in post-acute rehabilitation programs.
GIA®'s Role
GIA® offers a standardized and objective ADHD screening process within the digitalhumanOS™ framework.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.
Workflow Integration
Integrates seamlessly into existing post-acute care workflows, minimizing disruption to therapy sessions.
Improved Outcomes
Addressing ADHD can improve focus, attention, and overall engagement in rehabilitation activities.
Conclusion
By implementing GIA® for ADHD screening, post-acute care facilities can provide more personalized and effective rehabilitation services, optimizing patient outcomes and improving their overall quality of life.
Sources & References
- Translating AI Research into Reality: Summary of the 2025 Voice AI Symposium. Frontiers in Digital Health. DOI: 10.3389/fdgth.2026.1754426. Vanderbilt, MIT, Mayo Clinic, NIH Bridge2AI.
- Mapping the Neurophysiological Link Between Voice and Autonomic Function: A Scoping Review. 2025. Biology (MDPI). DOI: 10.3390/biology14101382.
- Scienza Health internal validation: 12.3M patients, 27B clinical events, 2,500+ speech biomarkers.
David Kaiser is the Founder and CEO of Scienza Health. He leads the development of GIA® and digitalhumanOS™, a clinically validated speech biomarker platform that screens for 46 cognitive and neurological conditions in under 5 minutes.
This content is intended for informational purposes and does not constitute medical advice. Editorially reviewed by David Kaiser, CEO of Scienza Health, for accuracy in post-acute care operations.
Frequently Asked Questions
Is it a diagnostic tool?
A screening tool, not a diagnosis.
Is it difficult to use?
Very user-friendly interface.
What kind of data is collected?
Attention and impulsivity metrics.
The Clinical Signal
Hear the latest episode on clinical AI screening in post-acute care.